Pharmerging Market by Product (OTC Drugs, Pharmaceuticals), Indication (Cancer & Autoimmune Diseases, Lifestyle Diseases), Distribution

The Pharmerging Market size was estimated at USD 1.53 billion in 2023, USD 1.68 billion in 2024, and is expected to grow at a CAGR of 9.74% to reach USD 2.94 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Pharmerging Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Pharmerging Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Pharmerging Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories Inc., AstraZeneca PLC, Bayer AG, Beckman Coulter, Inc., Bikal Ltd., CSL Behring LLC, Eli Lilly and Company, Farmson Pharmaceutical Gujarat Pvt. Ltd, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd, Johnson and Johnson, Lonza Group AG, Novartis AG, Pfizer, Inc., Rhombus Pharma Private Limited, Röchling Group, SCHOTT AG, Sun Pharmaceutical Industries Ltd., The RSA Group, and ZIM Laboratories Limited.

Market Segmentation & Coverage

This research report categorizes the Pharmerging Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product
- OTC Drugs
- Pharmaceuticals
  - Branded Prescription Drugs
  - Generic Drugs
Indication
- Cancer & Autoimmune Diseases
- Lifestyle Diseases
Distribution
- Clinics
- Drug Stores
- E-Commerce
- Hospitals

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

Market Penetration: It presents comprehensive information on the market provided by key players.
Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

What is the market size and forecast of the Pharmerging Market?
Which products, segments, applications, and areas should one consider investing in over the forecast period in the Pharmerging Market?
What are the technology trends and regulatory frameworks in the Pharmerging Market?
What is the market share of the leading vendors in the Pharmerging Market?
Which modes and strategic moves are suitable for entering the Pharmerging Market?

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Pharmerging Market, by Region

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing elderly population and rising burden of chronic diseases worldwide
5.1.1.2. Rising number of private hospitals and healthcare institutes
5.1.1.3. Extensive spending on healthcare globally and growing life expectancy among people
5.1.2. Restraints
5.1.2.1. High cost of research and development and strict price control
5.1.3. Opportunities
5.1.3.1. Potential demand from targeted therapeutics or personalized medicines
5.1.3.2. Emerging adoption of pharmerging in developing economies
5.1.4. Challenges
5.1.4.1. Concerns over IP protection and socio-politics with complex government approval process
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Pharmerging Market, by Product

6.1. Introduction
6.2. OTC Drugs
6.3. Pharmaceuticals
6.4.1. Branded Prescription Drugs
6.4.2. Generic Drugs

7. Pharmerging Market, by Indication

7.1. Introduction
7.2. Cancer & Autoimmune Diseases
7.3. Lifestyle Diseases

8. Pharmerging Market, by Distribution

8.1. Introduction
8.2. Clinics
8.3. Drug Stores
8.4. E-Commerce
8.5. Hospitals

9. Americas Pharmerging Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Pharmerging Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Pharmerging Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

13.1. Key Company Profiles
13.1.1. Abbott Laboratories Inc.
13.1.2. AstraZeneca PLC
13.1.3. Bayer AG
13.1.4. Beckman Coulter, Inc.
13.1.5. Bikal Ltd.
13.1.6. CSL Behring LLC
13.1.7. Eli Lilly and Company
13.1.8. Farmson Pharmaceutical Gujarat Pvt. Ltd
13.1.9. GlaxoSmithKline PLC
13.1.10. Glenmark Pharmaceuticals Ltd
13.1.11. Johnson and Johnson
13.1.12. Lonza Group AG
13.1.13. Novartis AG
13.1.14. Pfizer, Inc.
13.1.15. Rhombus Pharma Private Limited
13.1.16. Röchling Group
13.1.17. SCHOTT AG
13.1.18. Sun Pharmaceutical Industries Ltd.
13.1.19. The RSA Group
13.1.20. ZIM Laboratories Limited
13.2. Key Product Portfolio

14. Appendix

14.1. Discussion Guide
14.2. License & Pricing

List of Figures

FIGURE 1. PHARMERGING MARKET RESEARCH PROCESS
FIGURE 2. PHARMERGING MARKET SIZE, 2023 VS 2030
FIGURE 3. PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. PHARMERGING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. PHARMERGING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. PHARMERGING MARKET DYNAMICS
FIGURE 7. PHARMERGING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
FIGURE 8. PHARMERGING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. PHARMERGING MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 10. PHARMERGING MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
FIGURE 12. PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS PHARMERGING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS PHARMERGING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES PHARMERGING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES PHARMERGING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC PHARMERGING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC PHARMERGING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PHARMERGING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PHARMERGING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. PHARMERGING MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. PHARMERGING MARKET SHARE, BY KEY PLAYER, 2023

List of Tables

TABLE 1. PHARMERGING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. PHARMERGING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PHARMERGING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 6. PHARMERGING MARKET SIZE, BY OTC DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. PHARMERGING MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. PHARMERGING MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 9. PHARMERGING MARKET SIZE, BY BRANDED PRESCRIPTION DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. PHARMERGING MARKET SIZE, BY GENERIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 12. PHARMERGING MARKET SIZE, BY CANCER & AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. PHARMERGING MARKET SIZE, BY LIFESTYLE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 15. PHARMERGING MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. PHARMERGING MARKET SIZE, BY DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. PHARMERGING MARKET SIZE, BY E-COMMERCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. PHARMERGING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. AMERICAS PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 20. AMERICAS PHARMERGING MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS PHARMERGING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 24. ARGENTINA PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 25. ARGENTINA PHARMERGING MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 26. ARGENTINA PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 27. ARGENTINA PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 28. BRAZIL PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 29. BRAZIL PHARMERGING MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 30. BRAZIL PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 31. BRAZIL PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 32. CANADA PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 33. CANADA PHARMERGING MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 34. CANADA PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 35. CANADA PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 36. MEXICO PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 37. MEXICO PHARMERGING MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 38. MEXICO PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 39. MEXICO PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 41. UNITED STATES PHARMERGING MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES PHARMERGING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 45. ASIA-PACIFIC PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 46. ASIA-PACIFIC PHARMERGING MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 47. ASIA-PACIFIC PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 48. ASIA-PACIFIC PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 49. ASIA-PACIFIC PHARMERGING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 50. AUSTRALIA PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 51. AUSTRALIA PHARMERGING MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 52. AUSTRALIA PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 53. AUSTRALIA PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 54. CHINA PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 55. CHINA PHARMERGING MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 56. CHINA PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 57. CHINA PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 58. INDIA PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 59. INDIA PHARMERGING MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 60. INDIA PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 61. INDIA PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 62. INDONESIA PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 63. INDONESIA PHARMERGING MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 64. INDONESIA PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 65. INDONESIA PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 66. JAPAN PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 67. JAPAN PHARMERGING MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 68. JAPAN PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 69. JAPAN PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 70. MALAYSIA PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 71. MALAYSIA PHARMERGING MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 72. MALAYSIA PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 73. MALAYSIA PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 74. PHILIPPINES PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 75. PHILIPPINES PHARMERGING MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 76. PHILIPPINES PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 77. PHILIPPINES PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 78. SINGAPORE PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 79. SINGAPORE PHARMERGING MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 80. SINGAPORE PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 81. SINGAPORE PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 82. SOUTH KOREA PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 83. SOUTH KOREA PHARMERGING MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 84. SOUTH KOREA PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 85. SOUTH KOREA PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 86. TAIWAN PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 87. TAIWAN PHARMERGING MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 88. TAIWAN PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 89. TAIWAN PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 90. THAILAND PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 91. THAILAND PHARMERGING MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 92. THAILAND PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 93. THAILAND PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 94. VIETNAM PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 95. VIETNAM PHARMERGING MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 96. VIETNAM PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 97. VIETNAM PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA PHARMERGING MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA PHARMERGING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 103. DENMARK PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 104. DENMARK PHARMERGING MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 105. DENMARK PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 106. DENMARK PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 107. EGYPT PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 108. EGYPT PHARMERGING MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 109. EGYPT PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 110. EGYPT PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 111. FINLAND PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 112. FINLAND PHARMERGING MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 113. FINLAND PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 114. FINLAND PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 115. FRANCE PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 116. FRANCE PHARMERGING MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 117. FRANCE PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 118. FRANCE PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 119. GERMANY PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 120. GERMANY PHARMERGING MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 121. GERMANY PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 122. GERMANY PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 123. ISRAEL PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 124. ISRAEL PHARMERGING MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 125. ISRAEL PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 126. ISRAEL PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 127. ITALY PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 128. ITALY PHARMERGING MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 129. ITALY PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 130. ITALY PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 131. NETHERLANDS PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 132. NETHERLANDS PHARMERGING MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 133. NETHERLANDS PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 134. NETHERLANDS PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 135. NIGERIA PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 136. NIGERIA PHARMERGING MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 137. NIGERIA PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 138. NIGERIA PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 139. NORWAY PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 140. NORWAY PHARMERGING MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 141. NORWAY PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 142. NORWAY PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 143. POLAND PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 144. POLAND PHARMERGING MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 145. POLAND PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 146. POLAND PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 147. QATAR PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 148. QATAR PHARMERGING MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 149. QATAR PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 150. QATAR PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 151. RUSSIA PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 152. RUSSIA PHARMERGING MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 153. RUSSIA PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 154. RUSSIA PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 155. SAUDI ARABIA PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 156. SAUDI ARABIA PHARMERGING MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 157. SAUDI ARABIA PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 158. SAUDI ARABIA PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 159. SOUTH AFRICA PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 160. SOUTH AFRICA PHARMERGING MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 161. SOUTH AFRICA PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 162. SOUTH AFRICA PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 163. SPAIN PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 164. SPAIN PHARMERGING MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 165. SPAIN PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 166. SPAIN PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 167. SWEDEN PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 168. SWEDEN PHARMERGING MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 169. SWEDEN PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 170. SWEDEN PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 171. SWITZERLAND PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 172. SWITZERLAND PHARMERGING MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 173. SWITZERLAND PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 174. SWITZERLAND PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 175. TURKEY PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 176. TURKEY PHARMERGING MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 177. TURKEY PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 178. TURKEY PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 179. UNITED ARAB EMIRATES PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 180. UNITED ARAB EMIRATES PHARMERGING MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM PHARMERGING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 184. UNITED KINGDOM PHARMERGING MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM PHARMERGING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 186. UNITED KINGDOM PHARMERGING MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
TABLE 187. PHARMERGING MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 188. PHARMERGING MARKET SHARE, BY KEY PLAYER, 2023
TABLE 189. PHARMERGING MARKET LICENSE & PRICING

Companies Mentioned

Abbott Laboratories Inc.
AstraZeneca PLC
Bayer AG
Beckman Coulter, Inc.
Bikal Ltd.
CSL Behring LLC
Eli Lilly and Company
Farmson Pharmaceutical Gujarat Pvt. Ltd
GlaxoSmithKline PLC
Glenmark Pharmaceuticals Ltd
Johnson and Johnson
Lonza Group AG
Novartis AG
Pfizer, Inc.
Rhombus Pharma Private Limited
Röchling Group
SCHOTT AG
Sun Pharmaceutical Industries Ltd.
The RSA Group
ZIM Laboratories Limited

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	191
Published	March 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 1.68 Billion
Forecasted Market Value ( USD ) by 2030	$ 2.94 Billion
Compound Annual Growth Rate	9.7%
Regions Covered	Global
No. of Companies Mentioned	20

License	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access	This is a single user license, allowing one user access to the product.	€3404EUR$3,545USD£2,842GBP €3783EUR$3,939USD£3,157GBP
1 - 5 USER LICENSE PDF, Excel and Online Access	This is a 1-5 user license, allowing up to five users have access to the product.	€4277EUR$4,454USD£3,570GBP €4752EUR$4,949USD£3,967GBP
ENTERPRISE LICENSE PDF, Excel and Online Access	This is an enterprise license, allowing all employees within your organization access to the product.	€6023EUR$6,272USD£5,028GBP €6692EUR$6,969USD£5,586GBP

Pharmerging Market by Product (OTC Drugs, Pharmaceuticals), Indication (Cancer & Autoimmune Diseases, Lifestyle Diseases), Distribution - Forecast 2024-2030

FPNV Positioning Matrix

Market Share Analysis

Key Company Profiles

Market Segmentation & Coverage

The report offers valuable insights on the following aspects:

The report addresses key questions such as:

Table of Contents

Companies Mentioned

Methodology

Table Information

FPNV Positioning Matrix

Market Share Analysis

Key Company Profiles

Market Segmentation & Coverage

The report offers valuable insights on the following aspects:

The report addresses key questions such as:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Pharmerging Market Size, Share and Trends Analysis Report by Product (Pharmaceutical, Healthcare), Economy (Tier-1, Tier-2), Indication (Lifestyle Disease, Infectious Disease), and Region 2024-2030

Pharmerging - Global Strategic Business Report

Pharmerging Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

Specialty Drug Distribution Market by Disease Indication, Distributor Type, Distribution Type, End-User - Global Forecast 2025-2030

Pruritus Therapeutics Market by Therapy, Disease Indication, Distribution Channel, Route of Administration - Global Forecast 2025-2030